» Articles » PMID: 18496162

Recurrent Respiratory Papillomatosis: a Review

Overview
Journal Laryngoscope
Date 2008 May 23
PMID 18496162
Citations 117
Authors
Affiliations
Soon will be listed here.
Abstract

Recurrent respiratory papillomatosis (RRP), which is caused by human papillomavirus types 6 and 11, is the most common benign neoplasm of the larynx among children and the second most frequent cause of childhood hoarseness. After changes in voice, stridor is the second most common symptom, first inspiratory and then biphasic. Less common presenting symptoms include chronic cough, recurrent pneumonia, failure to thrive, dyspnea, dysphagia, or acute respiratory distress, especially in infants with an upper respiratory tract infection. Differential diagnoses include asthma, croup, allergies, vocal nodules, or bronchitis. Reports estimate the incidence of RRP in the United States at 4.3 per 100,000 children and 1.8 per 100,000 adults. Infection in children has been associated with vertical transmission during vaginal delivery from an infected mother. Younger age at diagnosis is associated with more aggressive disease and the need for more frequent surgical procedures to decrease the airway burden. When surgical therapy is needed more frequently than four times in 12 months or there is evidence of RRP outside the larynx, adjuvant medical therapy should be considered. Adjuvant therapies that have been investigated include dietary supplements, control of extra-esophageal reflux disease, potent antiviral and chemotherapeutic agents, and photodynamic therapies; although several have shown promise, none to date has "cured" RRP, and some may have serious side effects. Because RRP, although histologically benign, is so difficult to control and can cause severe morbidity and death, better therapies are needed. The potential for a quadrivalent human papilloma vaccine is being explored to reduce the incidence of this disease.

Citing Articles

Emergency Debulking of Recurrent Respiratory Papillomatosis: An Anesthesia Challenge.

Padvi A, Padvi N Cureus. 2024; 16(11):e74404.

PMID: 39723302 PMC: 11669302. DOI: 10.7759/cureus.74404.


Advances in Recurrent Respiratory Papillomatosis Treatment: Adjuvant Intralesional Bevacizumab's Impact, Potential and Insights from a Case Series Study.

Nayani D, Kasireddy M, Shankar T, Kumar P, Reddy L Indian J Otolaryngol Head Neck Surg. 2024; 76(5):3800-3806.

PMID: 39376305 PMC: 11456041. DOI: 10.1007/s12070-024-04612-z.


Recurrent respiratory papillomatosis: comparing in-office and operating room treatments.

Filauro M, Vallin A, Sampieri C, Benzi P, Gabella G, De Vecchi M Acta Otorhinolaryngol Ital. 2024; 44(4):233-241.

PMID: 39347548 PMC: 11441516. DOI: 10.14639/0392-100X-N2951.


Forecasting Disease Burden with a Dynamic Transmission Model of Human Papillomavirus and Recurrent Respiratory Papillomatosis in the United States.

Palmer C, Morais E, Tota J Viruses. 2024; 16(8).

PMID: 39205257 PMC: 11359546. DOI: 10.3390/v16081283.


Loss of Recurrent Laryngeal Papillomatosis following Postsurgical Treatment with dsRNA Interferon Inducer.

Sultanova A, Sokolovska L, cistjakovs M, Lifsics A Case Rep Infect Dis. 2024; 2024:6044987.

PMID: 39015517 PMC: 11250704. DOI: 10.1155/2024/6044987.